MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure September 28, 2018 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded a contract (HHSO100201800024C) of $14.8 million with options for an additional $32.0 million by the Biomedical Advanced Research and Development Authority (BARDA),
MappBio Announces Contracts with BARDA for ZMappTM and Additional Filovirus Medical Countermeasures Sep 29, 2017—(SAN DIEGO, CA)— Mapp Biopharmaceutical, Inc., announced today that it has been awarded a Project BioShield contract (HHSO100201700017C) of approximately $46 million by The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the
Researchers Discover First Human Antibodies That Work Against All Ebolaviruses May 18, 2017—(BRONX, NY)—After analyzing the blood of a survivor of the 2013-16 Ebola outbreak, a team of scientists from academia, industry and the government has discovered the first natural human antibodies that can neutralize and protect animals
Contact: Donna Ramirez donna.ramirez@utmb.edu 409-772-8791 FOR IMMEDIATE RELEASE April 5, 2017 Virus causes hemorrhagic fever often leading to death April 5, 2017 – GALVESTON, Texas – An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to
Contact: Kerry Lion klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE October 12, 2016 Therapy to Treat Ebola Shows Promise October 12, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today that results from the PREVAIL II clinical trial of ZMapp™ for treatment of Ebola
Contact: Perry Sacks psacks@skdknick.com 202-464-6611 FOR IMMEDIATE RELEASE August 8, 2016 Funds Will Allow Ebola Patients Expanded Access to Experimental Treatment August 8, 2016 – SAN DIEGO – Today, Mapp Biopharmaceutical, Inc. (Mapp Bio) announced it has received funding from Biomedical Advanced Research and Development Authority (BARDA), part of
Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE February 23, 2016 LeafBio Announces Conclusion of ZMapp™ Clinical Trial Therapy to Treat Ebola Shows Promise February 23, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today results from the Prevail II clinical trial
Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE January 07, 2016 Clinical Trials Begin on Antibody-based Prevention of HIV and Genital Herpes Leaf Bio’s MB66 Developed as Multipurpose Prevention Technology January 7, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today that
Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE October 15, 2015 ZMapp™ is Granted Orphan Medicinal Product Designation by the EMA Status May Enable Faster Approval of ZMapp™ October 15, 2015 – SAN DIEGO – LeafBio, Inc. (LeafBio), the commercial arm of Mapp Biopharmaceutical, Inc. (Mapp), announced today that
Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE September 17, 2015 ZMapp™ is Granted Fast Track Status by the FDA Status May Enable Faster Approval of ZMapp™ September 17, 2015 – SAN DIEGO – LeafBio, Inc. (LeafBio), the commercial arm of Mapp Biopharmaceutical, Inc. (Mapp), announced today that the